Back

Dual or single anti-thrombotic therapy in patients with atrial fibrillation after TAVI: a pre-specified analysis from the ENVISAGE-TAVI AF trial

20 February 2026 (09:45 - 10:30)
Organised by: Logo
Congress Presentation Part of: Poster session (2) - Pharmacology and pharmacotherapy Antiplatelet Drugs EAPCI Premium Access EAPCI Summit 2026 European Association of Percutaneous Cardiovascular Interventions (EAPCI)

About the speaker

Photo
Professor Marco Valgimigli

Cardiocentro Ticino Institute, Lugano (Switzerland)

4 More presentations in this session

Presentation thumbnail
Doctor A. Laino (Naples, IT)
Abstract Slides
Presentation thumbnail
Doctor A. Emara (Menoufia, EG)
Abstract
Presentation thumbnail
Mr J. Rogozarski (Vienna, AT)
Abstract Slides
Presentation thumbnail

Access the full session

Session thumbnail
Poster session (2) - Pharmacology and pharmacotherapy

The Event

Event poster

EAPCI Summit 2026

20 February 2026 09:45 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources